A5054685224- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Chronic Lymphocytic Leukemia Research
- Psoriasis: Treatment and Pathogenesis
- Bone health and osteoporosis research
- Biosimilars and Bioanalytical Methods
- Lymphoma Diagnosis and Treatment
- Hip and Femur Fractures
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Hepatitis C virus research
- Osteoarthritis Treatment and Mechanisms
- Inflammatory mediators and NSAID effects
- Orthopedic Surgery and Rehabilitation
- Health Systems, Economic Evaluations, Quality of Life
- Monoclonal and Polyclonal Antibodies Research
- Musculoskeletal pain and rehabilitation
- Peripheral Nerve Disorders
- Inflammatory Bowel Disease
- Tuberculosis Research and Epidemiology
- Bone and Joint Diseases
- Viral Infections and Immunology Research
- Pharmaceutical studies and practices
- Medication Adherence and Compliance
Université Laval
2016-2025
Centre hospitalier de l'Université Laval
2012-2024
Osteoporosis Canada
2014-2024
AbbVie (United States)
2024
Sanofi (France)
2024
Pfizer (United States)
2024
Janssen (Belgium)
2024
Amgen (United States)
2024
Fresenius Kabi (United States)
2024
Bristol-Myers Squibb (Switzerland)
2024
Abstract Objective To compare the efficacy of a single intraarticular corticosteroid injection, supervised physiotherapy program, combination two, and placebo in treatment adhesive capsulitis shoulder. Methods Ninety‐three subjects with <1 year's duration were randomized to 1 4 groups: group 1, injection (triamcinolone hexacetonide 40 mg) performed under fluoroscopic guidance followed by 12 sessions physiotherapy; 2, alone; 3, saline or 4, alone (placebo group). All taught simple home...
Objective To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety upadacitinib, a JAK 1‐selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoid arthritis ( RA ) who have experienced an inadequate response methotrexate MTX ). Methods In total, 1,629 were randomized (2:2:1) receive upadacitinib (15 mg once daily), placebo, (40 every other week) while continuing take stable background dose MTX. The primary end points...
This integrated analysis presents the safety profile of upadacitinib, a Janus kinase inhibitor, at 15 mg and 30 once daily in patients with moderately to severely active rheumatoid arthritis (RA).
To assess the long-term safety and efficacy of Janus kinase inhibitor upadacitinib versus adalimumab over 3 years in ongoing extension (LTE) SELECT-COMPARE, a randomised controlled phase trial patients with active rheumatoid arthritis inadequate response to methotrexate (MTX).Patients on stable background MTX were 2:2:1 15 mg, placebo or 40 mg. Patients an insufficient switched by week 26 from upadacitinib, upadacitinib. who completed 48-week double-blind period could enter LTE for up 10...
Objective To determine the effect of chondroitin sulphate (CS) treatment on cartilage volume loss, subchondral bone marrow lesions (BML), synovitis and disease symptoms in patients with knee osteoarthritis (OA). Methods In this pilot multicentre, randomised, double-blind, controlled trial primary OA, 69 clinical signs were randomised to receive CS 800 mg or placebo once daily for 6 months followed by an open-label phase which both groups received daily. Cartilage BML assessed MRI at baseline...
<h3>Background</h3> In SELECT-COMPARE, a randomised double-blind study, upadacitinib 15 mg once daily was superior to placebo or adalimumab on background methotrexate (MTX) for treating rheumatoid arthritis signs and symptoms inhibited radiographical progression versus at 26 weeks. Here we report 48-week safety efficacy in patients who continued their original medication were rescued the alternative insufficient response. <h3>Methods</h3> Patients MTX received mg, 48 Rescue without washout,...
To update the 1993 burden of illness osteoporosis in Canada, administrative and community data were used to calculate 2010 costs at $2.3 billion Canada or 1.3% Canada's healthcare expenditures. Prevention fractures high-risk individuals is key decrease financial osteoporosis.Since 1996 publication population has aged management changed. The study purpose was estimate current due Canadians 50 over.Analyses conducted using five national databases from Canadian Institute for Health Information...
To identify factors that are predictive of the outcomes greatest importance to patients-i.e., symptom relief, functional improvement, and satisfaction with surgery-following carpal tunnel release.We analyzed data from Maine Carpal Tunnel Study, a community-based study treatment for syndrome. In cohort patients who underwent release, preoperative physical examination was performed questionnaires were completed preoperatively at 6, 18, 30 months postoperatively. The assessed severity, upper...
The authors evaluated the relative responsiveness to change of generic versus disease-specific and unweighted weighted health status measures in carpal tunnel syndrome (CTS).Data were obtained from 196 subjects followed a prospective community-based cohort study Maine who underwent release (The Carpal Tunnel Syndrome Study). Patients before 6 months after surgery. disease-specific, severity score was derived validated Assessment Questionnaire. asked rate importance each symptom included...
To assess the safety and efficacy of upadacitinib versus adalimumab from SELECT-COMPARE over 5 years. Patients with rheumatoid arthritis inadequate response to methotrexate were randomised receive 15 mg once daily, placebo or 40 every other week, all concomitant methotrexate. By week 26, patients insufficient treatment rescued; remaining on switched upadacitinib. completing 48-week double-blind period could enter a long-term extension. Safety assessed through 264, radiographic progression...
Little is known about factors that predict return to work following carpal tunnel release. Patients enrolled in a prospective, community-based study of syndrome Maine were evaluated with standardized questionnaires preoperatively and 6 months Univariate multivariate analyses performed identify baseline associated disability surgery. Thirty-one 135 patients (23%) out because CTS The predominant preoperative variables absence due postoperatively logistic regression Workers' Compensation,...